



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsLtd@gmail.com

Website : www.concorddrugs.in

To,

Date: 18.10.2021

BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 18.10.2021

Ref: Our Company's letter dated 08.10.2021

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 18.10.2021 at 4:00 p.m. at the registered office of the company the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.09.2021. **(Enclosed)**
2. Limited review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.09.2021. **(Enclosed)**

The meeting concluded at 5.30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,  
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy  
Chairman & Whole time Director  
DIN: 01764665



Encl: as above


## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th september 2021

[Rs. in Lakhs]

Particulars	Quarterly ended			half year ended		Year ended
	30-Sep-21 (UnAudited)	30-Jun-21 (unAudited)	30-Sep-20 (UnAudited)	30-Sep-21 (UnAudited)	30-Sep-20 (UnAudited)	31-Mar-21 (Audited)
<b>I Revenue from Operations</b>						
a. Net sales from Operations	983.08	2,021.94	1,656.674	3,005.02	3,476.998	5,135.70
b. Other Operating Income	2.80	2.15	4.488	4.95	6.64	9.46
<b>II Other Income</b>						
<b>III Total Revenue (I+II)</b>	<b>985.88</b>	<b>2,024.10</b>	<b>1,661.16</b>	<b>3,009.98</b>	<b>3,483.64</b>	<b>5,145.16</b>
<b>IV Expenses</b>						
a. Cost of Material Consumed	743.09	1,566.49	1,384.379	2,309.58	2,881.951	4,049.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	72.21	18.48	26.732	53.73	123.448	168.67
c. Employees Benefit Expenses	103.82	104.88	101.090	208.70	188.090	375.55
d. Finance Costs	30.55	95.76	48.896	126.31	92.805	142.03
e. Depreciation and Amortisation expense	56.67	53.16	33.041	109.84	64.772	136.53
f. Other expenses	44.53	105.30	56.124	149.82	99.320	220.35
<b>Total Expenses</b>	<b>906.45</b>	<b>1,944.07</b>	<b>1,650.262</b>	<b>2,850.52</b>	<b>3,450.386</b>	<b>5,092.28</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>79.43</b>	<b>80.03</b>	<b>10.900</b>	<b>159.46</b>	<b>33.25</b>	<b>52.88</b>
<b>V Exceptional Items</b>						<b>376.32</b>
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>79.43</b>	<b>80.03</b>	<b>10.900</b>	<b>159.46</b>	<b>33.25</b>	<b>429.20</b>
<b>VII Tax Expense:</b>	<b>33.63</b>	<b>11.26</b>	<b>2.834</b>	<b>44.89</b>	<b>8.65</b>	<b>101.03</b>
<b>VIII a. Current tax</b>	27.741	24.68	1.686	52.42	7.14	47.07
<b>b. Deferred tax charge/credit</b>	5.892	13.42	1.148	7.53	1.50	53.96
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>45.794</b>	<b>68.770</b>	<b>8.066</b>	<b>114.564</b>	<b>24.607</b>	<b>328.17</b>
<b>X Other Comprehensive Income</b>						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>45.79</b>	<b>68.77</b>	<b>8.066</b>	<b>114.56</b>	<b>24.61</b>	<b>328.17</b>
<b>XI Paid-up equity share capital</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>
(Face value of the share- Rs. 10 each)						
<b>Other Equity</b>	<b>1,916.81</b>	<b>1,871.02</b>	<b>1,498.69</b>	<b>1,916.81</b>	<b>1,498.69</b>	<b>1,802.249</b>
<b>XII Earnings per share (of Rs. 10 each)</b>						
<b>XIII a. Basic (in Rs)</b>	0.52	0.79	0.092	1.31	0.281	3.75
<b>b. Diluted (in Rs)</b>	0.52	0.79	0.092	1.31	0.281	3.75

## Notes:

1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 18 th september ,2021
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The results are also available on the website of the Company www.concorddrugs.in

By Order of the Board  
For Concord Drugs LimitedManaging Director  
DIN: 01764665

Place: Hyderabad

Date: October 18, 2021

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana  
Un Audited Balance sheet as at 30th September , 2021 Rs in Lakhs

Particulars	Note	As At Sep 30, 2021	As At March 31, 2021
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Property, plant and equipment	3	1,287.49	1,319.15
(b) Capital Work-in Progress	3	26.68	-0.00
(b) Investment property	3	63.95	63.95
<b>Financial assets</b>			
(a) Loans & Advances	5	3.19	2.64
Other Non current assets	4	-	-
<b>Total Non - Current Assets</b>		<b>1,381.31</b>	<b>1,385.74</b>
<b>Current Assets</b>			
Inventories	7	1,317.91	1,187.18
<b>Financial assets</b>			
(a) Investments	6	2,047.58	2,072.80
(b) Trade receivables	8	25.58	3.55
(c) Cash and cash equivalents	8	2.10	2.10
(d) Bank balances other than (c) above	9	9.44	4.42
(e) Other Current Financial Assets	10	375.51	332.48
Other current assets			
<b>Total Current assets</b>		<b>3,778.13</b>	<b>3,602.54</b>
<b>Total Assets</b>		<b>5,159.44</b>	<b>4,988.27</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	11	874.38	874.38
Other equity	12	1,916.81	1,802.25
<b>Total Equity</b>		<b>2,791.19</b>	<b>2,676.62</b>
<b>Non-current liabilities</b>			
<b>Financial Liabilities</b>			
(a) Borrowings	13	223.99	60.30
(b) Trade payables			
Deferred tax liabilities, net	14	60.14	67.67
Provisions	15	255.45	208.38
Government Grants	13	32.61	36.92
<b>Total Non-current liabilities</b>		<b>572.19</b>	<b>373.27</b>
<b>Current liabilities</b>			
<b>Financial liabilities</b>			
(a) Borrowings	16	886.20	1,237.02
(b) Trade payables	17	213.41	314.77
(c) Other Current financial liabilities	18	127.71	-
Current tax liabilities, net	15	52.42	47.07
Other current liabilities	19	516.32	339.52
<b>Total Current liabilities</b>		<b>1,796.06</b>	<b>1,938.38</b>
<b>Total liabilities</b>		<b>2,368.25</b>	<b>2,311.65</b>
<b>Total Equity and liabilities</b>		<b>5,159.44</b>	<b>4,988.27</b>



Un Audited Statement Of Standalone Profit and Loss for the Period ended 30 Sep'21

Rs in Lakhs

	Particulars	Note	As at Sep 30,2021	As at March 31, 2021
I	<b>Revenue from Operations</b>			
	a. Net sales from Operations	20	3,005.025	5,135.70
II	<b>Other Income</b>	21	4.952	9.46
III	<b>Total Revenue (I+II)</b>		<b>3,009.977</b>	<b>5,145.16</b>
IV	<b>Expenses</b>			
	a. Cost of Material Consumed	22	2,309.577	4,049.15
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-53.732	168.67
	c. Employees Benefit Expenses	24	208.700	375.55
	d. Finance Costs	25	126.312	142.03
	e. Depreciation and Amortisation expense	3	109.837	136.53
	f. Other expenses	26	149.824	220.35
	<b>Total Expenses</b>		<b>2,850.52</b>	<b>5,092.28</b>
	<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>		<b>159.457</b>	<b>52.88</b>
V	<b>Exceptional Items</b>		0	376.32
VI	<b>Profit/ (Loss) before tax (V+VI)</b>		<b>159.457</b>	<b>429.20</b>
VII	<b>Tax Expense:</b>		<b>44.8930</b>	<b>101.03</b>
VIII	a. Current tax		52.4225	47.07
	b. Deferred tax charge/credit		-7.5295	53.96
IX	<b>Profit/ (Loss) for the period (VII-VIII)</b>		<b>114.5641</b>	<b>328.17</b>
X	<b>Other Comprehensive Income</b>			
	Items that will not be reclassified to profit or loss			-
	<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>		<b>114.56</b>	<b>328.17</b>
XI	<b>Paid-up equity share capital</b> (Face value of the share- Rs. 10 each)		<b>874.375</b>	<b>874.38</b>
XII	<b>Earnings per share (of Rs. 10 each)</b>			
XIII	a. Basic (in Rs)		1.31	3.75
	b. Diluted (in Rs)		1.31	3.75



S. N. Reddy

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement of Cash flow for the year ended 30th Sep, 2021

Rs in Lakhs

Particulars	As at	
	Sep 30, 2021	March 31, 2021
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit Before Tax	159.46	429.20
<i>Adjustments for:</i>		
<i>Profit on sale of ASSETS</i>		
Depreciation and amortisation expense	109.84	136.53
Finance costs	111.60	124.53
Interest income	(0.61)	(0.81)
Provision for Gratuity		
<b>Operating profit before working capital changes</b>	<b>380.28</b>	<b>689.46</b>
<i>Changes in working capital:</i> (Refer Note 40)		
<i>Adjustments for (increase) / decrease in operating assets:</i>		
<b>Financial Assets</b>		
Trade receivables	25.22	471.79
Loans and Advances	(0.55)	50.98
Other Non Current assets	-	37.85
Inventories	(130.73)	455.94
Other Current assets	(43.03)	29.71
Other bank balances	-	0.49
Other Current financial Assets	(5.03)	(0.29)
<i>Adjustments for increase / (decrease) in operating liabilities:</i>		
Trade payables	(101.36)	(964.85)
Borrowings		
Other current financial liabilities	127.71	
Other current liabilities	176.79	
Current tax liabilities, net	5.35	35.16
Provisions	47.07	(597.60)
Deferred tax on amalgamation		
<b>Cash generated from operations</b>	<b>481.75</b>	<b>208.64</b>
Net income tax paid	(52.42)	(47.07)
<b>Net cash flow from operating activities (A)</b>	<b>429.32</b>	<b>161.57</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-104.86	(367.40)
Proceeds from maturity of fixed deposits		
- Others	0.61	0.81
<b>Net cash (used in) / flow from investing activities (B)</b>	<b>(104.25)</b>	<b>(366.59)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity shares	-	-
Finance costs	-111.60	(124.53)
Repayment of Borrowings	163.68	(27.42)
Repayment of short term Borrowings	-350.82	367.92
Govt Grants	-4.30	(8.61)
Other equity Adjustment	-	-
<b>Net cash flow (used in) financing activities (C)</b>	<b>(303.04)</b>	<b>207.36</b>
<b>Net (decrease) in Cash and cash equivalents (A+B+C)</b>	<b>22.03</b>	<b>2.34</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>3.55</b>	<b>1.21</b>
Effect of exchange differences on translation of foreign currency Cash and cash equivalents	-	-
<b>Cash and cash equivalents at the end of the year (Refer Note (i) below)</b>	<b>25.58</b>	<b>3.55</b>
<b>* Comprises:</b>		
Balances with Banks	25.00	0.08
Others	0.58	3.46
	<b>25.58</b>	<b>3.55</b>



S. N. S. Reddy



# PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,  
Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.  
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

## Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2021, and the year to date results for the period 1 April 2021 to 30 September 2021, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six month period ended 30 September 2021 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pundarikashyam and Associates  
Chartered Accountants  
FRN: 011330S.**

*B. Surya Prakasa Rao*  
*Rao*

**B.Surya Prakasa Rao  
(Partner)  
MNo: 205125  
UDINNo: 21205125AAABDW6472**

**Place:Hyderabad  
Date: 18-10-2021.**